Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
16.25
-0.93 (-5.41%)
At close: May 12, 2025, 4:00 PM
16.04
-0.21 (-1.29%)
After-hours: May 12, 2025, 7:53 PM EDT
Telix Pharmaceuticals Revenue
In the year 2024, Telix Pharmaceuticals had annual revenue of 783.21M AUD with 55.85% growth. Telix Pharmaceuticals had revenue of 209.62M in the quarter ending December 31, 2024, with 48.82% growth.
Revenue (ttm)
783.21M AUD
Revenue Growth
+55.85%
P/S Ratio
10.88
Revenue / Employee
1,887,246 AUD
Employees
415
Market Cap
5.27B undefined
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 783.21M | 280.66M | 55.85% |
| Dec 31, 2023 | 502.55M | 342.45M | 213.90% |
| Dec 31, 2022 | 160.10M | 152.50M | 2,007.64% |
| Dec 31, 2021 | 7.60M | 2.38M | 45.71% |
| Dec 31, 2020 | 5.21M | 1.73M | 49.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
TLX News
- 5 days ago - Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy - GlobeNewsWire
- 14 days ago - Telix's Illuccix PSMA-PET Imaging Agent Approved in France - GlobeNewsWire
- 20 days ago - Telix Reports US$186M Q1 Revenue, Up 62% YOY - GlobeNewsWire
- 26 days ago - Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients - Benzinga
- 27 days ago - IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate - GlobeNewsWire
- 4 weeks ago - Telix Announces Cardinal Health for Gozellix Commercial Distribution - GlobeNewsWire
- 5 weeks ago - Telix Appoints Paul Schaffer as Chief Technology Officer - GlobeNewsWire
- 5 weeks ago - Telix Pharmaceuticals: Building A Radiopharma Powerhouse - Seeking Alpha